CAMBRIDGE, Mass., Dec. 1, 2021 /PRNewswire/ -- Akebia Therapeutics,
Inc. (Nasdaq: AKBA), a biopharmaceutical company with the
purpose to better the lives of people impacted by kidney disease,
granted 21 newly-hired employees options to purchase an aggregate
of 85,000 shares of Akebia's common stock on November 30, 2021, as inducements material to
each such employee's entering into employment with Akebia. The
options were granted in accordance with Nasdaq Listing Rule
5635(c)(4).
The options have an exercise price of $2.71 per share, which is equal to the closing
price of Akebia's common stock on the grant date. Each stock option
vests over four years, with 25% of the shares vesting on the first
anniversary of the grant date and the remaining 75% of shares
vesting quarterly thereafter, in each case, subject to the new
employee's continued service with Akebia. Each stock option has a
10-year term and is subject to the terms and conditions of Akebia's
Inducement Award Program and a stock option agreement covering the
grant.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated
biopharmaceutical company with the purpose to better the lives of
people impacted by kidney disease. The Company was founded in 2007
and is headquartered in Cambridge,
Massachusetts. For more information, please visit our
website at www.akebia.com, which does not form a part of this
release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301435652.html
SOURCE Akebia Therapeutics